Phathom Pharmaceuticals to Present at Jefferies 2019 London Healthcare Conference
BUFFALO GROVE, Ill.--(BUSINESS WIRE)--Nov 13, 2019--
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that David Socks, President and CEO, will present at the Jefferies 2019 London Healthcare Conference on Wednesday, November 20 at 10:40 a.m. GMT at the Waldorf Hilton, London.
To access the live webcast and subsequent archived recordings for this presentation, which will be available for 30 days, please visit the Phathom Pharmaceuticals website at www.phathompharma.com.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a novel potassium competitive acid blocker (P-CAB) in late-stage development for the treatment of acid-related disorders. For more information about Phathom, visit the company’s website at www.phathompharma.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20191113005602/en/
CONTACT: David Socks
Sam Brown Inc. Healthcare Communications
KEYWORD: EUROPE UNITED STATES UNITED KINGDOM NORTH AMERICA ILLINOIS
INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH CLINICAL TRIALS
SOURCE: Phathom Pharmaceuticals, Inc.
Copyright Business Wire 2019.
PUB: 11/13/2019 04:05 PM/DISC: 11/13/2019 04:05 PM